Immune Tolerance Articles & Analysis
17 news found
Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells. Evaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized induction of immune ...
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced it is set to join the broad-market Russell 3000 and the Russell 2000 Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022 ...
Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in which VE303 was well tolerated and highly active at preventing Clostridioides difficile infection recurrence in subjects at high risk of recurrence Further CONSORTIUM study analysis shows that the VE303 high dose led to more robust colonization, which in turn correlated with prevention of recurrence Safety and ...
Preclinical data on combination with co-stimulatory 4-1BB agonists or adoptive T cell transfer showed potent T cell responses and significant tumor control Preclinical data also expand evidence on arenaviral immunotherapy targeting tumor self-antigens, reinforcing scientific approach for HB-300 program in prostate cancer Poster presentations at AACR underscore the versatility of ...
Phase 1 multicenter dose-escalation and dose-expansion trial evaluating IO-202 as a monotherapy and in combination with an anti-PD-1 is initiated and expected to enroll 200 patientswith advanced solid tumors This is the second clinical trial for the IO-202 program; its first Phase 1 trial is currently enrolling patients with acute myeloid leukemia (AML) or chronic myelomonocytic leukemia ...
Prellis Biologics, Inc. (Prellis), a Bay Area biotherapeutics company, announced today that it has entered into a collaboration and license option agreement with Sanofi S.A. focused on the discovery of antibodies with Prellis’ first-in-class external human immune system (EXIS). The collaboration leverages Prellis’ ability to engineer fully-human lymph node organoids (LNOs™) and ...
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will participate in a reside chat and 1x1 investor meetings at Oppenheimer's 32nd Annual Healthcare Conference on Tuesday, March ...
INOVIO (NASDAQ: INO) announced today that fourth quarter 2021 financial results will be released after the market close on March 1, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. A live and archived version of the audio presentation will be available online at ...
CD Genomics is a leading services company committed to providing global customers with the most comprehensive analytic services, including a broad range of microbial genomic solutions to support research and development. The company announced microbiome profiling services, alongside bioinformatic analysis technology to help researchers understand the significance of human and animal microbiota. ...
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced the company is rapidly moving to evaluate its COVID-19 DNA vaccine candidates INO-4800 and INO-4802 against the emerging B.1.1.529 (Omicron) variant of concern. Concurrently, INOVIO ...
INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that several volunteers have been dosed with its DNA-based, intradermal Ebola vaccine candidate, INO-4201, as part of a randomized, placebo-controlled, Phase 1b clinical trial ...
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help treat cancer, and HPV-associated diseases, announced today that eight company-sponsored presentations will be given this week at the 34th International Papillomavirus Conference (IPVC) , which is being held virtually from today, ...
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the launch of its #PeanutAllergyStrong patient engagement campaign. “Supporting peanut allergy patients and their loved ones has always been the central mission at ...
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell ...
A COVID-19 vaccine candidate developed by a UB spinoff company has progressed to human trials in South Korea, according to a UBNow story. The vaccine candidate, called EuCorVac-19, was jointly developed by Buffalo biotech company POP Biotechnologies and South Korean biotech company EuBiologics. POP Biotechnologies was founded in 2015 by former UB students Kevin Carter and Jonathan Smyth and UB ...
Siolta Therapeutics, a clinical-stage biotech company, announced today it has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H. The series B funding involved participation from top-tier investors and venture firms, including series A investors Khosla Ventures and Marc Benioff as well as new investors Seventure (Health for Life Capital ...
The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Siolta Therapeutics to its coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products. This new addition brings MTIG's membership to five companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products. Siolta ...